系统性红斑狼疮患者重症COVID-19的危险因素:2020-2021年美国大型代表性行政索赔数据库的真实世界分析
这项回顾性队列研究纳入2890例合并COVID-19的系统性红斑狼疮(SLE)成人患者,发现利妥昔单抗、肾衰竭、Medicaid保险、复杂性高血压等是进展为重症COVID-19的显著危险因素,接种疫苗在所有患者中具有显著保护作用(OR 0.68),但在既往使用贝利尤单抗、利妥昔单抗或糖皮质激素者中保护作用不显著。
要点
- 2890例SLE合并COVID-19患者中500例(16.4%)发生COVID-19相关住院。
- 利妥昔单抗(OR 2.92)、肾衰竭(OR 2.15)、Medicaid(OR 2.01)、复杂性高血压(OR 1.96)与重症风险升高相关。
- 疫苗接种总体保护显著(OR 0.68),但既往使用贝利尤单抗、利妥昔单抗或糖皮质激素者中不显著。
核心结论
- 某些慢性合并症和SLE用药增加SLE患者进展为重症COVID-19的比值,但疫苗接种提供显著保护。
- 疫苗有效性可能被SLE治疗削弱。
- 作者建议在SLE患者中鼓励暴露前预防和加强疫苗接种等保护措施。
研究设计与样本
- 回顾性队列研究,使用Merative™ MarketScan®数据库识别SLE成人患者。
- 患者需在2020年4月1日前一年(基线)连续参保,并在2020年4月1日至死亡、参保结束或2021年12月31日中最早者之间诊断为COVID-19。
- 重症COVID-19定义为因COVID-19诊断住院。
- 评估2020年4月1日人口学特征、基线合并症、COVID-19诊断前≤30天糖皮质激素使用及诊断前≤6个月其他SLE用药。
- 采用向后逐步logistic回归估计患者特征和疫苗接种与进展为重症COVID-19的比值比。
主要发现
- 2890例合并COVID-19的SLE患者中,500例(16.4%)发生COVID-19相关住院。
- 进展为重症COVID-19的显著危险因素包括利妥昔单抗(OR 2.92,95%CI 1.67至5.12)、肾衰竭(OR 2.15,95%CI 1.56至2.97)、Medicaid(对比Commercial;OR 2.01,95%CI 1.58至2.57)、复杂性高血压(OR 1.96,95%CI 1.38至2.77)及感染时间等。
- 疫苗接种在所有合并COVID-19的SLE患者中具有显著保护作用(OR 0.68,95%CI 0.54至0.87)。
- 在既往使用贝利尤单抗、利妥昔单抗或糖皮质激素者中,疫苗接种的保护作用不显著。
临床怎么用
- 作者建议在SLE患者中鼓励暴露前预防和加强疫苗接种等保护措施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify risk factors for progression to severe COVID-19 and estimate the odds of severe COVID-19 associated with vaccination among patients with systemic lupus erythematosus (SLE). METHODS: This retrospective cohort study identified adults with SLE in the Merative™ MarketScan® Databases. Patients were continuously enrolled the year before 1 April 2020 (baseline) and had a COVID-19 diagnosis between 1 April 2020 and the earliest of death, enrolment end or 31 December 2021. Severe COVID-19 was defined as hospitalisation with a COVID-19 diagnosis. Demographics on 1 April 2020, baseline comorbidities, corticosteroid use ≤30 days before COVID-19 diagnosis and other SLE medication use ≤6 months before COVID-19 diagnosis were assessed. Vaccination was identified by claims for a COVID-19 vaccine or vaccine administration. Backward stepwise logistic regression estimated odds of progression to severe COVID-19 associated with patient characteristics and vaccination. RESULTS: Among 2890 patients with SLE with COVID-19, 500 (16.4%) had a COVID-19-related hospitalisation. Significant risk factors for progression to severe COVID-19 included rituximab (OR (95% CI) 2.92 (1.67 to 5.12)), renal failure (2.15 (95% CI 1.56 to 2.97)), Medicaid (vs Commercial; 2.01 (95% CI 1.58 to 2.57)), complicated hypertension (1.96 (95% CI 1.38 to 2.77)) and time of infection, among others. Vaccination had a significant protective effect (0.68(95% CI 0.54 to 0.87)) among all patients with SLE with COVID-19, but the effect was not significant among those with prior use of belimumab, rituximab or corticosteroids. CONCLUSIONS: Certain chronic comorbidities and SLE medications increase the odds of progression to severe COVID-19 among patients with SLE, but vaccination confers significant protection. Vaccine effectiveness may be attenuated by SLE treatments. Protective measures such as pre-exposure prophylaxis and booster vaccines should be encouraged among patients with SLE.
引用
- Calabrese C, Atefi G, Evans KA, et al. Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020-2021. RMD Open. 2023. PMID: 37591618. doi:10.1136/rmdopen-2023-003250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。